Revolution Medicines, Inc. (NASDAQ:RVMD) received FDA approval for Rasonque, or daraxonrasib, following an expedited review. The once-daily oral RAS inhibitor is approved for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
Revolution Medicines, Inc. set a wholesale acquisition cost (WAC) of $39,800 for a 30-day supply. Twelve 30-day supplies would total $477,600 at WAC before discounts, rebates, or assistance. Rasonque is available in the United States, with (ON)Path offering insurance navigation and financial-assistance resources, including copay support for eligible commercially insured patients.
The approval was based on RASolute 302, a randomized Phase 3 trial involving 500 patients with previously treated metastatic pancreatic adenocarcinoma. In the overall population, median overall survival reached 13.2 months with Rasonque versus 6.7 months with chemotherapy. The hazard ratio of 0.40 represented a 60% lower hazard of death during trial follow-up. Median progression-free survival was 7.2 months versus 3.6 months, while objective response rates were 30% and 11%, respectively.
Bull Case
The survival benefit gives Rasonque a strong clinical argument for reimbursement. Pancreatic cancer is aggressive, treatment options after progression are limited, and Rasonque improved overall survival, progression-free survival, and response rates in a randomized comparison. Oral dosing may also reduce the burden of intravenous chemotherapy.
The approved population is broader than a single mutation-defined subgroup. Rasonque can be prescribed with or without an identified RAS tumor mutation and does not require a companion diagnostic. That reduces testing friction within the approved treatment setting.
The approval also validates the RAS(ON) inhibitor strategy of Revolution Medicines, Inc.. Rasonque directly targets active RAS signaling, while additional programs are studying the medicine in first-line and adjuvant pancreatic cancer and evaluating other RAS-directed candidates in pancreatic and lung cancers. Successful expansion could turn one approval into a broader oncology franchise.
Bear Case
The price creates a demanding access test. Wholesale acquisition cost is not the same as a patient’s out-of-pocket expense, but it influences payer negotiations, prior-authorization requirements, and treatment budgets. Assistance programs can reduce costs for qualifying patients without guaranteeing broad, rapid reimbursement across commercial insurance, Medicare, and other coverage channels.
The initial label also excludes many patients receiving standard first-line multiagent therapy. Growth beyond the current setting depends on additional Phase 3 trials, regulatory approvals, and evidence that Rasonque works in earlier disease settings or combinations. Those outcomes remain unproven.
Safety and adherence require attention as well. In the pooled pancreatic-cancer safety population, dermatologic toxicity occurred in 86% of patients, stomatitis in 57% and diarrhea in 63%; Grade 3 rates were 10%, 9% and 6%. In RASolute 302, adverse reactions led to dose interruptions in 69% and dose reductions in 37%. Revolution Medicines, Inc. must now demonstrate physician adoption and consistent payer coverage during its first commercial launch.
Hedge Fund Sentiment
The filings available so far reflect positions held before Revolution Medicines, Inc. reported the FDA approval and U.S. pricing of Rasonque. Insider Monkey’s database showed 105 hedge funds holding Revolution Medicines, Inc. at the end of 2Q2026, down from 106 funds three months earlier.
Conclusion
Rasonque delivered the survival evidence needed to support a meaningful clinical breakthrough. The randomized results, broad RAS coverage, and oral dosing create a credible case for adoption and validate the platform of Revolution Medicines, Inc..
Commercial value will depend on how quickly coverage converts eligible patients into treated patients at a sustainable net price. Rasonque has cleared the clinical hurdle. Access, launch execution, and successful expansion into earlier treatment settings will determine how much of that achievement becomes durable revenue.
READ NEXT: Main Street Capital’s (MAIN) Blowout Exit Fuels A Bigger Dividend and Here is Why Chevron (CVX) is a Favorite Among Hedge Funds
This article is originally published at Insider Monkey.
Hedge Fund Resource Center